Pharmacy Pearls: GLP-1 RAs for Weight Loss

September 2nd, 2021 | Pharmacy Pearls•Diabetes

This edition of Pharmacy Pearls reviews some of the evidence supporting the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss, including a review of the newest approved product, Wegovy (semaglutide). There is also a comparison to a select list of other currently-approved weight loss agents relative to average weight loss and expected side effects. Email the Pharmacy Team with any questions or feedback you may have.

Taking too long?

Reload document

Open in new tab

Download PDF [245.96 KB]

135 Corporate Woods, Suite 320
Rochester, New York 14623-1466

Phone: (585) 758-7823
Fax: (585) 424-1268

Website by:

This is not an offer to purchase or a solicitation of an offer to purchase any securities or interest in Accountable Health Partners, LLC (AHP). An offer will only be made by means of a confidential private placement memorandum and subscription agreement.

ABI Value	Interpretation	Recommendation
Greater than 1.4	Calcification/vessel hardening	Refer to vascular specialist
1.0 - 1.4	Normal	None
0.9 - 1.0	Acceptable	None
0.8 - 0.9	Some arterial disease	Treat risk factor
0.5 - 0.8	Moderate arterial disease	Refer to vascular specialist
Less than 0.5	Severe arterial disease	Refer to vascular specialist

Pharmacy Pearls: GLP-1 RAs for Weight Loss

Pharmacy Pearls: GLP-1 RAs for Weight Loss

GENERAL COVID-19 INFORMATION